Jong-In Park

12PUBLICATIONS

30CO-AUTHORS

Molecular targetsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Social epidemiology

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (12)

Sort by Publication Date:

|Jun 08, 2026

Combination of Selpercatinib and Trametinib Overcomes Resistance to RET Inhibitors in RET-Mutant Medullary Thyroid Carcinoma.

|Jan 14, 2026

Phase II Study of Dabrafenib and Trametinib in Patients With Tumors With BRAFV600E Mutations: Updated Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol H.

April K S Salama, Victoria Wang, Erin R Macrae

|Jun 27, 2024

Wenjing Chen, Young Shin Song, Han Sai Lee

|Feb 20, 2024

Selpercatinib combination with the mitochondria-targeted antioxidant MitoQ effectively suppresses RET-mutant thyroid cancer.

Wenjing Chen, Sophie Dream, Pui-Yin Leung

|Oct 14, 2023

Tumor Cell Resistance to the Inhibition of BRAF and MEK1/2.

Wenjing Chen, Jong-In Park

|Jun 10, 2023

MAPK-ERK Pathway.

Jong-In Park

Pageof 2

Frequent Collaborators

Pui-Kei Wu

Wenjing Chen

Rebekah L Gundry

Hao Shao

Jason E Gestwicki

Seung-Keun Hong

Chien-Wei Lin

Seon-Kyu Kim

Seon-Young Kim

Young Joo Park

Frequent Collaborators

Pui-Kei Wu

Wenjing Chen

Rebekah L Gundry

Hao Shao